12 citations
,
January 2014 in “Journal of international medical research” Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
1 citations
,
February 2013 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
22 citations
,
June 2017 in “Journal of the Formosan Medical Association” The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
2 citations
,
January 2018 in “Elsevier eBooks” Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.